Valuation: CalciMedica, Inc.

Market Cap 19.56M 16.75M 15.67M 14.35M 26.93M 1.87B 27.28M 185M 72.22M 940M 73.43M 71.83M 3.11B P/E 2026 *
-0.95x
P/E 2027 * -0.54x
Enterprise Value 19.56M 16.75M 15.67M 14.35M 26.93M 1.87B 27.28M 185M 72.22M 940M 73.43M 71.83M 3.11B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
81.47%
Yield 2026 *
-
Yield 2027 * -
1 day-3.90%
1 week-9.18%
Current month-38.69%
1 month-17.64%
3 months-2.51%
6 months+13.33%
Current year-90.70%
1 week 0.56
Extreme 0.5608
0.69
1 month 0.56
Extreme 0.5608
1
Current year 0.46
Extreme 0.4606
7.2
1 year 0.46
Extreme 0.4606
7.2
3 years 0.46
Extreme 0.4606
8.38
5 years 0.46
Extreme 0.4606
8.59
10 years 0.46
Extreme 0.4606
8.59
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 73 2007-03-31
Chief Executive Officer 63 2019-08-31
Director of Finance/CFO 36 2024-10-31
Director TitleAgeSince
Chairman 85 2023-03-19
Chairman 63 -
Director/Board Member 76 2020-04-30
Date Insider Type Main position Quantity % Market Cap.
7/2/26
Bering Capital LLC
OtherCompany 2,244,164 7.3013%
7/2/26 Free

Director

20,000 0.0651%
6/25/26 Free

Chairman

1,182,621 7.4859%
Change 5-day change 1-year change 3-year change Capi.($)
-3.90%-9.18%-77.95%-81.37% 19.56M
-3.00%+2.27%+73.26%+109.90% 72.12B
+1.90%+23.53%+59.48%+94.82% 65.85B
+5.12%+25.22%+5.13%-5.86% 29.28B
+0.55%+1.64%-4.63%+480.92% 27.47B
+2.74%+12.98%+54.92%+25.77% 26.7B
+0.47%+6.12%+37.01%-15.31% 20.06B
+1.82%-6.67%+251.36%+388.91% 18.22B
+0.94%+3.36%+15.30%+548.19% 16.4B
+0.73%+5.54%+39.99%+151.77% 13.4B
Average +0.74%+6.86%+45.39%+169.77% 28.95B
Weighted average by Cap. +0.74%+9.48%+58.02%+157.84%

Financials

2026 *2027 *
Net sales - -
Net income -12.75M -10.92M -10.22M -9.35M -17.55M -1.22B -17.78M -121M -47.07M -613M -47.86M -46.82M -2.03B -27.1M -23.22M -21.72M -19.89M -37.32M -2.59B -37.81M -257M -100M -1.3B -102M -99.56M -4.31B
Net Debt - -
Logo CalciMedica, Inc.
CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).
Employees
16
Date Price Change Volume
26-08-21 US$0.5728 -1.78% 271,591
26-08-20 US$0.5832 -4.88% 1,087,453
26-08-19 US$0.6131 -3.90% 423,648
26-08-18 US$0.6380 -3.70% 103,618
26-08-17 US$0.6625 -1.87% 75,988
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.5728USD
Average target price
10.00USD
Spread / Average Target
+1,645.81%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CALC Stock